Lilly says Foundayo 17.2 mg outperforms oral semaglutide 25 mg on weight loss, A1C in indirect comparison study

Bitget2026/09/29 07:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eli Lilly disclosed an indirect comparison suggesting Foundayo outperformed higher-dose oral semaglutide on weight and blood-sugar control in type 2 diabetes.
Results were presented at the European Association for the Study of Diabetes meeting in Milan.
Analysis extends ACHIEVE-3, a 52-week trial that previously showed Foundayo beat lower-dose oral semaglutide on the same outcomes.
Readout supports Foundayo’s competitive positioning as a once-daily oral GLP-1 option with fewer dosing constraints than oral semaglutide.
Oral semaglutide 25 mg remains unapproved in the US, leaving the comparison centered on a dose still under review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609290300PR_NEWS_USPR_____DE57460) on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lilly says Foundayo 17.2 mg outperforms oral semaglutide 25 mg on weight loss, A1C in indirect comparison study

You may also like

Crypto prices